Developed by industry-leading doctors and scientists, First Person optimizes neurochemistry by stimulating the production of specific neurotransmitters in the brain tied to three main functions: focus, mood, and sleep. The precision-targeted mushrooms are paired with a curated blend of nutraceuticals to support the body’s natural neural production of the dopamine, oxytocin, or GABA neurotransmitters to help achieve the desired mental state.
The supplements are intended to help create an ideal environment for both immediate and long-term brain health and performance. With continued use, First Person may support the body’s natural ability to reduce oxidative stress and promote healthy cell regeneration, and may be used as a natural, effective alternative to caffeine, anti-stress or sleep aids. Unlike anything else on the market today, First Person’s products have been formulated to avoid serotonin receptors, so they may work both independently and as a highly effective complement to existing psychedelic microdosing protocols.
“We are thrilled to open peoples’ minds to the transformative power of mushrooms,” said Co-Founder and Chief Innovation Officer, Chris Claussen. “We believe that mushrooms are without a doubt the future of the wellness industry, and our products will offer a transformative solution to anyone looking to improve their overall well-being and cognitive performance.”
As a vertically integrated company, First Person uses the highest quality, natural ingredients and a proprietary production process, First Grown™, which could enable it to unlock the full medicinal benefits of mushrooms. First Grown™ was developed by First Person’s innovation team to supply the highest quality mushroom ingredients to businesses.
As part of its mission to improve cognitive health, the company is actively building one of the most robust culture libraries of psychedelic mushrooms to advance research and development, standardization, product development, consumer testing, engagement, and feedback, through its operation in Jamaica. This opportunity may provide access to unique and novel compounds for product innovation beyond psilocybin.
“As we conduct cutting edge research on psychedelic mushrooms, we are simultaneously innovating and exploring the very powerful benefits that legal, non-psychedelic functional mushrooms have on cognitive health,” said Co-Founder and Director of Business Development, Joseph Claussen. “This is only the beginning for us as we pave a new path forward in mushroom innovation.”
First Person launches with three supplements. Sunbeam is intended to promote motivation and focus by stimulating the production of dopamine to offer a natural, powerful and caffeine-free boost. Golden Hour is intended to promote connection and joy by stimulating the production of the oxytocin to mitigate stress and boost the mind-body connection. Lastly, Moonlight is intended to promote deep, restorative sleep by stimulating the production of the…
Read more:FIRST PERSON LAUNCHES INNOVATIVE PRECISION-TARGETED COGNITIVE SUPPLEMENTS TO ACTIVATE